BioPorto A/S (BIOPOR.CO)
| Previous close | 1.6720 |
| Open | 1.6700 |
| Bid | 1.7540 x 0 |
| Ask | 1.7800 x 0 |
| Day's range | 1.6520 - 1.7800 |
| 52-week range | 1.0020 - 2.9200 |
| Volume | |
| Avg. volume | 611,725 |
| Market cap | 589.037M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings date | 10 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
- Globe Newswire
BioPorto Announces Annual Results for the Year ended December 31, 2022
March 30, 2023Announcement no. 4 BioPorto Announces Annual Results for the Year ended December 31, 2022 COPENHAGEN, Denmark and BOSTON, MA, USA, March 30, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced financial results for the year ended December 31, 2022 and business progress for the fourth quarter of 2022. Recent Highlights For the year ended December 31, 2022: Total revenue of DKK 29.0 million / USD 4.1 million, a 19% increase over the prior yearAdjusted EBITD
- Globe Newswire
BioPorto Announces Financial Guidance for 2023
March 29, 2023Announcement no. 3 BioPorto Announces Financial Guidance for 2023 COPENHAGEN, Denmark and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces financial guidance for 2023. BioPorto’s three strategic activities in 2023 are to: Grow revenues in European and other markets that accept CE MarkFocus on the US NGAL test’s regulatory pathwayExpand the total addressable market for NGAL tests Key assumptions relating to the 2023 outlo
- Globe Newswire
US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.
March 29, 2023Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. COPENHAGEN, DENMARK and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces that Chris Lindop, Chairman of the Board of Directors, has for personal reasons decided not to stand for re-election at the upcoming ordina
